Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance

BMC Medical Research Methodology

Volumn 12, Issue , 2012, Pages

  Castro, Hannah ^a   Pillay, Deenan ^b   Sabin, Caroline ^b   Dunn, David T ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG EFFECT; EPIDEMIOLOGY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREVALENCE; STATISTICAL MODEL; UNITED KINGDOM; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIAS (EPIDEMIOLOGY); DRUG RESISTANCE, VIRAL; GREAT BRITAIN; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; PREVALENCE;

EID: 84858044888     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-12-30     Document Type: Article

References (9)

1. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Pillay D, Antivir Ther 2004 9 5 695 702 15535406 (Pubitemid 39434332)
2. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. UK Group on Transmitted HIV Drug Resistance, BMJ 2005 331 7529 1368 1371 16299012
3. Prevalence of primary genotypic resistance in a UK centre: comparison of primary HIV-1 and newly diagnosed treatment-naive individuals. Fox J, Hill S, Kaye S, Dustan D, McClure M, Fidler S, Mackie NE, AIDS 2007 21 237 239 10.1097/01.aids.0000247577.26375.ef 17197816 (Pubitemid 46036933)
4. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) study. The UK Collaborative HIV Cohort Steering Committee, HIV Med 2004 5 115 124 15012652
5. The AIDS incubation period in the UK estimated from a national register of HIV seroconverters. UK Register of HIV Seroconverters Steering Committee, AIDS 1998 12 659 667 9583607
6. Health Protection Agency, Scottish Centre for Infection and Environmental Health, National Public Health Service for Wales, Communicable Disease Surveillance Centre Northern Ireland, Unlinked Anonymous Surveys Steering Group, Renewing the Focus: HIV and Other Sexually Transmitted Infections in the UK in 2002 London: Health Protection Agency 2003
7. Update of the drug resistance mutations in HIV-1: December 2009. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD, Top HIV Med 2009 17 5 138 145 20068260
8. The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT, on behalf of the UK Collaborative Group on HIV Drug Resistance, J Acquir Immune Defic Syndr 2008 49 196 204 10.1097/QAI. 0b013e318185725f 18769348
9. Differential persistence of transmitted HIV-1 drug resistance mutation classes. Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant RM, Cortes R, Deeks SG, Hecht FM, J Infect Dis 2011 203 8 1174 1181 10.1093/infdis/jiq167 21451005